Clinical Trials

Title   [595286-17] A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)
Description   The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. The study will also further characterize the safety of CDX-011 treatment in this patient population.
IRB Number   14-123
Treatment   Oncology - Breast Cancer
Status   Active
Principal Name   Carole Norden, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us